Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.62 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.49 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.67 |
| ▸ | MPO | P05164 | 4/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172293 | 0.88 | TAAR1 (0.63) | TAAR1MPOCYP1A2GLACYP3A4 | |
| SCHEMBL17033966 | 0.85 | TAAR1 (0.66) | TAAR1MPOCYP1A2GLACYP3A4 | |
| SCHEMBL25046557 | 0.85 | MPO (0.58) | TAAR1MPOCYP1A2GLACYP3A4 | |
| SCHEMBL172536 | 0.83 | TAAR1 (0.58) | TAAR1MPOCYP1A2GLACYP3A4 | |
| SCHEMBL2572378 | 0.81 | TAAR1 (0.55) | TAAR1MPOCYP1A2GLACYP3A4 | |
| SCHEMBL22762068 | 0.81 | TAAR1 (0.59) | TAAR1MPOCYP1A2GLACYP3A4 | |
| SCHEMBL22762050 | 0.81 | TAAR1 (0.59) | TAAR1MPOCYP1A2GLACYP3A4 | |
| SCHEMBL28507125 | 0.80 | TAAR1 (0.54) | TAAR1MPOCYP1A2GLACYP3A4 | |
| SCHEMBL6894181 | 0.80 | TAAR1 (0.64) | TAAR1MPOCYP1A2GLACYP3A4 | |
| SCHEMBL28964921 | 0.80 | TAAR1 (0.64) | TAAR1MPOCYP1A2GLACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0957092-A1 | Ring-closed dihydropyridines and their use in the preparation of pharmaceutical compositions | Boehringer Ingelheim Pharma KG (DE) | 1999-11-17 | — | — | EP | disclosed |
| US-5861412-A | CARDIOPROTECTIVE AGENTS, CEREBROPROTECTIVE AGENTS, AGENTS FOR TREATING CHRONIC INFLAMMATORY PROCESSES, ANTIPROLIFERATIVE AGENTS AND AS AGENTS FOR TREATING ULCERATIVE COLITIS AND CROHN'S DISEASE | BOEHRINGER INGELHEIM KG (DE) | 1999-01-19 | — | — | US | disclosed |
| US-5674878-A | ANTIPROLIFERATIVE,-TUMOR AND -CARCINOGENIC AGENTS; ULCERATIVE COLITIS; CROHN*S DISEASE | BOEHRINGER INGELHEIM KG (DE) | 1997-10-07 | — | — | US | disclosed |
| US-5643919-A | TREATMENT OF CROHN*S DISEASE, ULCERATIVE COLITIS | BOEHRINGER INGELHEIM KG (DE) | 1997-07-01 | — | — | US | disclosed |
| EP-0647220-A1 | RING-CLOSED DIHYDROPYRIDINES AND THEIR USE IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 1995-04-12 | — | — | EP | disclosed |
| WO-1994000435-A1 | RING-CLOSED DIHYDROPYRIDINES AND THEIR USE IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM KG (DE) | 1994-01-06 | — | — | WO | disclosed |